Background--Patients with symptomatic severe aortic stenosis and a history of chest radiation therapy represent a complex and challenging cohort. It is unknown how transcatheter aortic valve replacement (TAVR) compares with surgical aortic valve replacement in this group of patients, which was the objective of this study.
R adiation therapy to the chest is an important element in the treatment of various malignancies such Hodgkin's lymphoma and breast cancer. Efforts have been made to reduce radiation injury to chest structures, but most of these came into effect only in the new millennium. In addition, clinical consequences of radiation-induced heart disease are not seen until %10 to 20 years after radiation therapy. 1, 2 Thus, at present, radiation-induced heart disease remains a clinical reality, an element of which is valvular heart disease in nearly half of the patients. 3 Management of valve disease in these patients is complicated by the presence of both, regurgitation and stenosis, of multiple cardiac valves, as well as concomitant coronary artery, myocardial, and pericardial disease. Furthermore, mediastinal, pulmonary, and/or pericardial fibrosis pose particular challenges for surgical interventions in this patient population. Percutaneous approaches may thus present a more favorable option for these patients (eg, transcatheter aortic valve replacement [TAVR] ) in case of severe aortic stenosis (AS).
Since its introduction in 2002 by Cribier, TAVR has become an important treatment strategy for patients with severe AS.
(SAVR) or TAVR among high-risk patients with severe symptomatic AS (stage D) was changed from Class IIa (LOE B) to Class I (LOE A). 5, 6 For patients with severe symptomatic AS (stage D) and intermediate surgical risk, TAVR has been shown to be a reasonable alternative to SAVR (Class IIa, LOE B-R). In patients with radiation-induced heart disease, TAVR may have higher feasibility and higher clinical effectiveness than SAVR. 7 Supporting data, however, are not available because retrospective analyses have not been performed and clinical trials such as the PARTNER (Placement of Aortic Transcatheter Valve) trial were not stratified to a level that would allow for randomized comparisons of TAVR versus SAVR in this patient population. The current retrospective cohort study was performed to address this gap in knowledge.
Methods
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure unless approved by all authors after review and conclusion of a reasonable request.
Patient Population
The Mayo Clinic STS (Society of Thoracic Surgery) and TVT (Transcatheter Valve Therapy) registries were screened for patients who underwent TAVR or SAVR for severe AS and had a history of chest radiation for malignancy (total number of patients screened from February 2011 to April 2018, n=1210 for TAVR and n=1707 for SAVR). 8 The Mayo Clinic Institutional
Review Board approved this study as well as a waiver of the requirement to obtain informed consent in accordance with 45 CFR 46.116 and a waiver of HIPAA authorization in accordance with applicable HIPAA regulations.
Clinical and Laboratory Measurements
The STS-TVT database review included age, sex, current smoking status, hypertension, hyperlipidemia, diabetes mellitus, atrial fibrillation, heart failure, New York Heart Association class 2 weeks before procedure, chronic lung disease, prior myocardial infarction, prior percutaneous coronary angioplasty, prior coronary artery bypass grafting (CABG), prior stroke, peripheral arterial disease (PAD), radiation history, and immunosuppression. Porcelain aorta was defined according to published guidelines. 9 STS risk score was calculated for all patients as per standard practice. 9 The STS/American College of Cardiology TVR registry-based risk score was used to calculate expected in-hospital mortality among cancer patients. 10 Clinical records were reviewed to determine the timing and type of malignancy for which the patients received chest radiation. All participants underwent echocardiography before the aortic valve procedure. Left ventricular ejection fraction was measured by the biplane Simpson method (biplane method of disk summation). 11 Stroke volume was determined by simplified continuity equation using the Doppler method. Aortic valve area (AVA) and gradient were measured by simplified continuity and Bernoulli equations, respectively. 12,13 Valvular regurgitation was graded by experienced echocardiographers at our institution according to established guidelines. 14 Low left ventricular stroke volume index (LV-SVI) was defined as <35 mL/m 2 and low-flow low-gradient (LF-LG) AS by the combination of AVA ≤1 mm 2 , mean gradient <40 mm Hg, and low LV-SVI.
15,16
Outcome Parameters
In-hospital outcomes included all-cause mortality, myocardial infarction, stroke, major adverse cardiac events, postoperative atrial fibrillation, pacemaker placement, respiratory arrest, renal failure requiring dialysis, cardiac tamponade, bleeding, and length of hospital stay. In general, these were analyzed in accordance with the standards set forth by the Valve Academic Research Consortium (VARC-2). 9 Major adverse cardiac events were defined as the composite of death, myocardial infarction, or stroke. Postoperative atrial fibrillation was defined as new onset (ie, normal sinus rhythm before and atrial fibrillation after valve replacement). Postdischarge mortality and readmission
Clinical Perspective
What Is New?
• In patients with symptomatic severe aortic stenosis after chest radiation therapy, surgical aortic valve replacement performs worse and transcatheter aortic valve replacement performs better than predicted by Society of Thoracic Surgery score.
• In this patient population, transcatheter aortic valve replacement is associated with lower adjusted 30-day and 1-year mortality, less postoperative atrial fibrillation, and shorter duration of hospital stay but higher readmission rates.
What Are the Clinical Implications?
• Transcatheter aortic valve replacement might be the preferred choice for patients with symptomatic severe aortic stenosis and history of chest radiation.
• Further studies should be conducted on the preferred role of transcatheter aortic valve replacement in this unique patient population, preferably in a randomized clinical trial design.
events were calculated based on registry and chart review data. Echocardiographic estimations of aortic valve gradient and presence of at least moderate prosthetic or periprosthetic regurgitation at discharge as well as at 6 months and 1 year postprocedure were collected as supplementary outcome data.
Statistical Analyses
Normally 
Results

Patient Population
A total of 110 patients with symptomatic severe AS and a history of chest radiation were identified, 55 patients in each group (ie, 4.6% and 3.2% of all patients undergoing TAVR and SAVR, respectively) ( Figure S1 ). Lymphoma (56.4%) and breast cancer (34.6%) were the 2 most common indications for radiation therapy. The characteristics of the study population by procedural group are summarized in Table 1 . Patients in the TAVR group were older and had a more extensive cardiovascular history including atrial fibrillation, PAD, heart failure, or prior pacemaker implantation. These patients also more commonly had chronic lung disease. The average mean aortic valve gradient was lower in the TAVR group (Table 1) , whereas no difference was found for AVA, LV-SVI, right ventricular systolic pressure, or other echocardiographic parameters. There was a numeric but not statistically significant difference in the prevalence of LF-LG AS between the TAVR and SAVR groups.
Outcome Analyses
As shown in Table 2 , the aortic valve area was larger and the mean aortic valve gradient was lower in the TAVR group than in the SAVR group at discharge and at 1 year. In relation to baseline values, the gain in aortic valve area was higher in the TAVR group but the reduction in the mean gradient was lower ( Table 2 ). The change in mean aortic valve (AV) gradient per change in AV area was lower in the TAVR than in the SAVR group, driven by the LF-LG patients in the TAVR group (mean change in AV gradient per change in AV area was À11.4AE5.5 in TAVR patients with LF-LG versus À22.1AE15.8 in TAVR patients without LF-LG, P=0.003). No difference was found between TAVR and SAVR in regard to the percentage of at least moderate prosthetic or periprosthetic aortic valve regurgitation. A similar decrease in the number of patients with ≥ moderate mitral regurgitation was seen in both groups after aortic valve replacement, with 4 in the TAVR and none in the SAVR group remaining (Table 2) .
In-hospital crude all-cause mortality and major adverse cardiac events rates were numerically but not statistically lower in the TAVR group than in the SAVR group, as detailed in Table 3 . The rate of postoperative atrial fibrillation was significantly lower in the TAVR group than in the SAVR group (3.6% versus 32.7%, respectively, P<0.001). Patients who underwent TAVR had a shorter length of hospital stay than patients in the SAVR group In the crude analysis, there was no difference in 30-day or 1-year all-cause mortality ( Figure 1A and B). After inverse probability of treatment weighting adjusting for STS score, 30-day and 1 year all-cause mortality were significantly lower Cox proportional hazards analysis in the entire cohort identified prior myocardial infarction, PAD, LF-LG AS, and STS risk score as predictors of mortality. In the multivariate model, LF-LG AS and STS risk score remained significant predictors of 1-year mortality adjusting for TAVR (Table 4) . LF-LG AS was predictive of 1-year mortality in the TAVR group alone in both the unadjusted and the inverse probability of treatment weighting-adjusted analyses ( Figure S2 ). Less than half of the LF-LG AS patients survived up to 1 year after TAVR ( Figure S2 ).
Regarding readmission rates, these were higher in the TAVR than in the SAVR group, about 2-fold at 30 days and more than 5-fold at 90 days ( Table 3 ). The reasons for readmissions are listed in Table S1 . Heart failure was the leading readmission diagnosis in TAVR patients.
Discussion
The present study demonstrates that TAVR compared with SAVR for native severe AS in patients with prior chest radiation is associated with (1) older age, higher STS scores, and more baseline comorbidities; (2) lower incidence of postprocedural atrial fibrillation and shorter hospital stay; and (3) lower adjusted 30-day and 1-year all-cause mortality.
A recent study from the Cleveland Clinic on a matched cohort of more than 300 SAVR patients showed that those with prior chest radiation therapy more commonly have more severe coronary artery and pulmonary disease. 17 In a smaller study of 26 TAVR patients with a history of prior chest radiation therapy, matched 1:1 to patients without such history, radiation therapy patients presented more frequently with PAD, pacemaker therapy, and moderate/severe MR (mitral regurgitation). 18 On the contrary, the very first analysis on TAVR in this patient cohort noted a lower cardiovascular risk factor burden, less PAD, and less atrial fibrillation. 7 In our study, we found that patients in the TAVR group were older, had a higher prevalence of atrial fibrillation and prior pacemaker implantation, PAD, CABG-treated coronary artery disease, heart failure, and chronic lung disease than SAVR patients. Also, their New York Heart Association functional class status was more advanced. The STS score was higher in the TAVR and lower in the SAVR group than previously reported. Collectively, these data indicate that patients with prior chest radiation therapy are more complex, and that those with the highest degree of comorbidity are more likely to be directed to TAVR. It is interesting that TAVR patients had a lower mean aortic gradient change per mean aortic valve area change than SAVR patients. Their mean gradient, however, was already lower before the procedure despite similar aortic valve areas. This constellation was previously recognized as a unique feature of patients who underwent SAVR with a history of chest radiation and was attributed to lower LV-SVIs. 17 Similarly, in TAVR patients with a history of chest radiation, Donnellan et al noted that 63% of patients had a low LV-SVI. 19 A LV-SVI <35 mL/m 2 is the defining characteristic for LF-LG AS (ie, AVA ≤1 mm 2 but mean gradient <40 mm Hg. 15, 16 As reported before, patients with radiation exposure to the chest generally have a preserved ejection fraction and the reduction in stroke volume is the consequence of restrictive changes. 20 In combination with severely elevated afterload over time, as in case of severe AS, these changes could be more profound. Indeed, the prevalence of LF-LG AS was 2 to 4 times higher in our population (20%) than the reported 5% to 10% in the general AS population. 17 It was this subgroup of TAVR patients with LF-LG that experienced the least reduction in mean AV gradient per AVA gained after valve replacement. Future studies will have to explore these hemodynamic aspects further. Donnellan et al pointed out that patients undergoing SAVR with a history of chest radiation require more inotropic support and blood transfusions, have longer intensive care unit and overall length of hospital stay, more frequently undergo pacemaker therapy, and experience a higher rate of atrial fibrillation, stroke, and mortality. 17 Furthermore, Ghoneim et al noted a 10% in-hospital mortality in nearly 50 patients with a history of chest radiation therapy after SAVR. 21 Postprocedural deaths were seen exclusively with combined SAVR and CABG. 21 Bouleti et al found that the procedural success of TAVR was lower in the radiation than in the nonradiation group. 18 In our study, TAVR and SAVR patients had generally similar in-hospital outcomes with the following exceptions. The rate of postoperative atrial fibrillation was significantly lower and the length of hospital stay was significantly shorter in the TAVR group. The latter finding is remarkable in view of the more comorbid nature of this cohort of patients. A lower rate of atrial fibrillation is very meaningful, given its association with an increased risk of in-hospital mortality, higher stroke incidence, and prolonged hospital stay. [22] [23] [24] [25] [26] [27] Importantly, the preprocedural prevalence of active atrial fibrillation was not higher in the TAVR group, and the rate of atrial fibrillation in the SAVR group is in keeping with previous reports. 22, 28, 29 Whereas patients without prior chest radiation have a survival after SAVR that matches the general population, those with prior chest radiation have a median life expectancy of only 7 years (48% versus 7% mortality at 6AE3 years of follow-up, P<0.001). 17 Ghoneim et al recorded similar outcomes over similar follow-up times: postdischarge mortality was 47% and the average time to death was 2AE1 and 1.4AE1.6 years (average 5-year survival rates 65% versus 37%) after isolated SAVR and SAVR+CABG, respectively. 21 Despite these numbers, it is important to note the life- extending benefit of SAVR in this patient population. 17 For TAVR, Bouleti et al showed that patients with a history of chest radiation more frequently had severe bleeding and developed heart failure with hemodynamic complications; 30-day mortality was 8% versus 5% based on the STS score. 18 Over a median follow-up of 3 to 4 years, 58% in the radiation group and 42% in the control group died; average 5-year survival rates were 33% and 42%, respectively. This compares to 3-and 5-year survival rates of 61% and 46%, respectively, in the UK TAVR registry. 30 Dijos et al found no differences in major outcome parameters in TAVR patients with and without chest radiation at 30 days and 6 months. 7 In the most recent analysis on AS patients with a history of chest radiation, Donnellan et al observed in-hospital, 1-year, and 2-year survival rates of 96%, 91%, and 86%, respectively, after TAVR compared with 96%, 86%, and 80% after SAVR. 19 In our study, we likewise found no significant difference in in-hospital mortality, but 30-day and 1-year mortality was lower with TAVR than with SAVR once adjusted for intergroup baseline STS score differences. Importantly, chest radiation patients undergoing SAVR had a higher than predicted mortality, which confirms the clinical intuition that this represents a high-risk population. On the contrary, those undergoing TAVR had a lower than predicted mortality. The better than expected performance of the TAVR group was also seen using the STS-American College of Cardiology-TVR registry risk score; however, this score was designed to stratify for in-hospital mortality only. 10 Finally, because percutaneous coronary intervention can be safely performed in patients with severe AS and those undergoing TAVR, 19, 31 a transcatheter approach might be particularly attractive in patients in need of interventions on both aortic valve and coronary arteries, given the above-outlined outcome data for SAVR and CABG. In regard to mortality predictors, Donnellan et al outlined the risk associated with a history of chest radiation for AS patients in general; post SAVR, the STS score remained the only other independent predictor. 17 After TAVR, the same group found the STS score and baseline LV-SVI to be predictive. 19 Bouleti et al identified the following to be independent predictors of mortality: PAD, no b-blocker before TAVR, serum creatinine, and infectious complications. 18 Herein, we identified the STS score as an independent predictor of 1-year mortality for both SAVR and TAVR patients. Though not designed for TAVR, the STS score has been shown to perform equally well, especially after transfemoral TAVR. 32 Indeed, the STS score is one of the strongest predictors of survival after TAVR in the general AS population. [33] [34] [35] In the current analysis, though, the strongest predictor of 1-year mortality in the overall and especially in the TAVR cohort was LF-LG AS. It remains to be shown if and how this information could be utilized to guide patient management. Prior studies have outlined the poor long-term survival of patients with LF-LG AS (32% versus 66% 10-year survival) and the doubling of 5-year survival rates with SAVR despite higher operative mortality. 36 Recent studies outline the favorable performance of TAVR in this patient population and very likely it will play an increasingly important role in LF-LG AS patients. 16, 37, 38 In terms of morbidity, a nearly 3-fold higher rate of readmissions within 90 days was reported for AS patients with prior chest radiation after SAVR. 17 Following TAVR in AS in general, readmission rates as high as 24% at 30 days and 44% at 1 year have been reported, relating to both noncardiac (especially respiratory disease, infections, and bleeding) and cardiac (eg, heart failure and arrhythmias) causes. 39 In the current study, readmission rates after TAVR were not quite as high, but still significantly higher than for SAVR. Of interest, all readmissions in the SAVR group and nearly all readmissions in the TAVR group were cardiac-or surgery-related. Proper postprocedural follow-up is therefore very important, and providers need to be prepared to meet the higher demands of this patient population.
Limitations
The limitations of this study include its nonrandomized and observational nature, which could have significantly affected the results because of confounding factors and significant comorbidities in the TAVR compared with the SAVR group. Inverse probability of treatment weighting was thus used to adjust for confounders, but any such statistical technique remains limited with small cohort sizes. Moreover, 25.5% of patients in the SAVR group underwent concomitant CABG, which could have worsened the clinical outcomes of this group. However, there were no observed numerical differences in outcomes between combined SAVR and CABG and isolated SAVR in our study. Of further note, 1-year echocardiographic data were not available in significant number of patients in both groups. This being said, this study still provides the first and largest comparison of clinical outcomes post TAVR versus SAVR in patients with a history of chest radiation. A larger multicenter study with larger sample population and longer follow-up will be necessary to confirm the results of this study. Because of dropout in follow-up, proportional hazard assumption was violated when analyzing long-term outcome data up to 3 years, and thus these were not reported. Finally, we could not determine the association of AS and radiation dose because such details of radiation history were not available in the majority of patients.
Conclusions
In patients with severe AS and a history of chest radiation for cancer, TAVR is associated with a favorable short-and intermediate-term prognosis. TAVR is associated with lower mortality than predicted by STS score along with less postoperative atrial fibrillation and shorter duration of hospital stay. In this complex and challenging patient population, TAVR might be the preferred choice of valve replacement. Larger cohort studies and ideally adequately powered randomized clinical trials are needed to further consolidate such a recommendation.
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